FOxTROT - Fluoropyrimidine, Oxaliplatin and Targeted Receptor Pre-Operative Therapy: a Controlled Trial in High-Risk Operable Colon Cancer

Trial Profile

FOxTROT - Fluoropyrimidine, Oxaliplatin and Targeted Receptor Pre-Operative Therapy: a Controlled Trial in High-Risk Operable Colon Cancer

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Panitumumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colon cancer
  • Focus Therapeutic Use
  • Acronyms FOxTROT
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 31 Mar 2018 to 1 Dec 2019.
    • 01 Aug 2017 Status changed from completed to active, no longer recruiting.
    • 03 Dec 2015 Accrual to date is 86% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top